azd1386
Small moleculeexperimental
Clinical trial activity
11 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00692146)
Timeline
Indications
Mechanism of action
- Vanilloid receptorANTAGONIST
TRPV1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O- Mol. weight
- 423.78 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545039 ↗
Also known as
- azd1386
- azd1386
- azd1386
- azd-1386
- azd-1386
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01019928 | Phase 2 | Nov 1, 2009 | Aarhus University, AstraZeneca |
| NCT00976534 | Phase 2 | Sep 1, 2009 | AstraZeneca |
| NCT00945178 | Phase 1 | Aug 1, 2009 | AstraZeneca, Parexel |
| NCT00878501 | Phase 2 | Mar 1, 2009 | AstraZeneca |
| NCT00832169 | Phase 1 | Jan 1, 2009 | AstraZeneca |
| NCT00736658 | Phase 1 | Jun 1, 2008 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
| NCT00711048 | Phase 1 | Jun 1, 2008 | Aarhus University, AstraZeneca |
| NCT00714337 | Phase 1 | Jun 1, 2008 | AstraZeneca, Parexel |
| NCT00672646 | Phase 2 | Apr 1, 2008 | AstraZeneca, Lifetree Clinical Research |
| NCT00690079 | Phase 1 | Feb 1, 2008 | AstraZeneca |
| NCT00692146 | Phase 1 | Jan 1, 2008 | AstraZeneca |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 11 | 11 | 2 | 2008 |
| Aarhus University | Academic/Hospital | 2 | 0 | 2 | 2008 |
| Parexel | For profit | 2 | 0 | 1 | 2008 |
| Kyushu Clinical Pharmacolgy Reasearch Clinic | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Lifetree Clinical Research | For profit | 1 | 0 | 1 | 2008 |
5 organizations
Page 1 / 1